<SEC-DOCUMENT>0001193125-18-227822.txt : 20180726
<SEC-HEADER>0001193125-18-227822.hdr.sgml : 20180726
<ACCEPTANCE-DATETIME>20180726162605
ACCESSION NUMBER:		0001193125-18-227822
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180725
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180726
DATE AS OF CHANGE:		20180726

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMGEN INC
		CENTRAL INDEX KEY:			0000318154
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				953540776
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37702
		FILM NUMBER:		18972062

	BUSINESS ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320
		BUSINESS PHONE:		(805)447-1000

	MAIL ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMGEN
		DATE OF NAME CHANGE:	19870305
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d583316d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of The Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported) July&nbsp;25, 2018 </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>AMGEN INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name
of registrant as specified in its charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>001-37702</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>95-3540776</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(IRS Employer<BR>Identification No.)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>One Amgen Center Drive</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Thousand Oaks, California</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>91320-1799</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>805-447-1000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;26, 2018, Amgen Inc. (the &#147;Company&#148;) publicly
announced that Sean E. Harper is retiring from the role of the Company&#146;s Executive Vice President, Research and Development, and David M. Reese, the Company&#146;s current Senior Vice President, Translational Sciences and Oncology, has been
appointed by the Company&#146;s Board of Directors (the &#147;Board&#148;) to serve as Executive Vice President, Research and Development, each effective as of July&nbsp;26, 2018. The Company also announced that Anthony&nbsp;C. Hooper is retiring
from the role of the Company&#146;s Executive Vice President, Global Commercial Operations, and Murdo Gordon, Chief Commercial Officer of Bristol-Myers Squibb Company, has been appointed by the Company&#146;s Board to serve as Executive Vice
President, Global Commercial Operations, each effective as of September&nbsp;3, 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Departure of Executive Vice President,
Research and Development </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;26, 2018, Dr.&nbsp;Harper will retire from the role of the Company&#146;s Executive Vice
President, Research and Development, and will continue to be employed by the Company in a non-executive officer capacity to assist in the transition, which transition period is currently expected to extend until the end of 2018. At that time,
Dr.&nbsp;Harper will be retirement eligible under the Company&#146;s plans and policies and, upon his departure from the Company at the end of 2018, he will receive the retirement benefits set forth in the Company&#146;s plans and described in the
Company&#146;s filings, including the Company&#146;s 2018 Proxy Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Departure of Executive Vice President, Global Commercial
Operations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;3, 2018, Mr.&nbsp;Hooper will retire from the role of the Company&#146;s Executive Vice President,
Global Commercial Operations, and will continue to be employed by the Company in a non-executive officer capacity to assist in the transition, which transition period is currently expected to extend through 2019. At that time, Mr.&nbsp;Hooper will
be retirement eligible under the Company&#146;s plans and policies and, upon his departure from the Company at the end of 2019, he will receive the retirement benefits set forth in the Company&#146;s plans and described in the Company&#146;s
filings, including the Company&#146;s 2018 Proxy Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Additional Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of the press release announcing Dr.&nbsp;Harper&#146;s and Mr.&nbsp;Hooper&#146;s retirements from the roles of the Company&#146;s
Executive Vice President, Research and Development and Global Commercial Operations, respectively, and the appointments of Dr.&nbsp;Reese as the Company&#146;s new Executive Vice President, Research and Development, and Mr.&nbsp;Murdo as the
Company&#146;s new Executive Vice President, Global Commercial Operations, is attached as Exhibit 99.1 to this Current Report on Form 8-K. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d583316dex991.htm">Press Release, dated July&nbsp;26, 2018 </A></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">AMGEN INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: July&nbsp;26, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" NOWRAP>By:&nbsp;&nbsp;&nbsp;&nbsp; <U>/<FONT STYLE="font-size:8pt">S</FONT>/ &nbsp;Jonathan P.
Graham&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Jonathan P. Graham</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Senior Vice President, General Counsel</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and Secretary</P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d583316dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g583316g86k48.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Amgen Center Drive</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Thousand&nbsp;Oaks,&nbsp;CA&nbsp;91320-1799</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">805-447-1000</FONT></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">www.Amgen.com</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>News Release</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMGEN ANNOUNCES SUCCESSION PLANS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR TWO EXECUTIVE OFFICERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THOUSAND OAKS,
Calif. (July 26, 2018) &#150; As part of Amgen&#146;s (NASDAQ:AMGN) planned executive succession to address upcoming retirements, the Company announced transition plans for two of its executive vice presidents today. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After more than 21 years of leadership in the biopharmaceutical industry, including the past 16 years with Amgen, Sean E. Harper, M.D., executive vice
president of Research and Development, has decided to retire and plans to pursue opportunities in the early-stage biotechnology community. David M. Reese, M.D., currently senior vice president of Translational Sciences and Oncology at Amgen, has
been appointed as executive vice president of Research and Development, effective today. Reese will report to Robert A. Bradway, chairman and chief executive officer. Harper will remain at Amgen for a period of time to facilitate the transition to
Reese. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2018, Anthony C. Hooper, currently executive vice president of Global Commercial Operations, will retire from this role. Murdo
Gordon, chief commercial officer of Bristol-Myers Squibb Company, has been named as executive vice president of Global Commercial Operations, effective Sept. 3, 2018. Gordon will report to Bradway. Hooper will also remain at Amgen for a period of
time to facilitate the transition to Gordon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I would like to thank both Sean and Tony for the important contributions they have made to Amgen, each
bringing their own vital experiences and skills,&#148; said Bradway. &#147;They leave the Company having established strong foundations within Research and Development and Global Commercial Operations for the future. It is a testament to their
leadership and accomplishments that they have attracted such exceptional talent to succeed them.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am looking forward to having Dave and
Murdo join us in their new leadership roles,&#148; Bradway added. &#147;With their deep combined expertise, they will add meaningfully to helping advance Amgen&#146;s mission of serving patients.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development (R&amp;D) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Harper, 55, joined
Amgen in 2002 as vice president of Development and assumed a series of roles with increasing responsibility, becoming executive vice president of Research and Development in February 2012. During his tenure, Harper led Amgen in achieving new product
approvals for medicines in cardiovascular disease, oncology, neuroscience and kidney disease; in establishing a leading presence in human genetics; and in expanding the Company&#146;s global R&amp;D footprint while transforming its capabilities.
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AMGEN ANNOUNCES SUCCESSION PLANS FOR TWO EXECUTIVE OFFICERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> PAGE
 2
 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In his new role, Reese, 55, assumes full responsibility for Amgen&#146;s global Research and Development
activities. Since joining Amgen in 2005, Reese has served in a breadth of leadership roles, including in Development, Medical Sciences, as head of Discovery Research and in Translational Sciences, where he had responsibility for introducing all of
Amgen&#146;s early medicines into clinical development. Prior to joining Amgen, Reese served on the faculty at the University of California, Los Angeles (UCLA) and the University of California, San Francisco. In addition, he was director of Clinical
Research for the Breast Cancer International Research Group (BCIRG) and a <FONT STYLE="white-space:nowrap">co-founder,</FONT> president and chief medical officer of Translational Research International (TORI), a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">not-for-profit</FONT></FONT> academic clinical research organization. Reese is a graduate of Harvard College and the University of Cincinnati College of Medicine. He completed his training in Internal Medicine and
Hematology/Oncology at the UCLA School of Medicine. Reese has published extensively in the fields of clinical research and translational medicine. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Commercial Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With more than 30 years in
the biopharmaceutical industry at the time of his hiring, Hooper, 63, joined Amgen in 2011 as executive vice president of Global Commercial Operations. During his tenure, Hooper led the transformation of Amgen&#146;s commercial organization, while
growing sales by nearly 50&nbsp;percent, with launches of six new <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> medicines for serious diseases and expansion into 50 new countries. In addition, Hooper
established Amgen&#146;s new biosimilars business, which began launching products this year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gordon, 52, who will assume Hooper&#146;s role, has been
Bristol-Myers Squibb&#146;s Chief Commercial Officer since June 2016. In this role he was responsible for commercial strategy across the globe, including all sales and marketing activities, as well as customer operations, access and pricing. Prior
to his current role, Gordon served as head of worldwide markets with responsibility for the promotion of all the company&#146;s brands globally. He moved to the U.S. in 2003 where he held senior commercial leadership positions in cardiovascular,
neuroscience, oncology and immunology, as well as access and government affairs &#150; all areas of continuing focus and importance for Amgen. Gordon joined Bristol-Myers Squibb in 1989 in Canada, after receiving a Bachelor of Science in Cell and
Molecular Biology from Concordia University, Montreal. In addition, he participated in the General Management Program, CEDEP at INSEAD, Fontainebleau, France. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Amgen </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amgen is committed to unlocking the
potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities
of disease and understand the fundamentals of human biology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for
solutions that improve health outcomes and dramatically improve people&#146;s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world&#146;s leading independent biotechnology companies, has reached millions of patients
around the world and is developing a pipeline of medicines with breakaway potential.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, visit <U>www.amgen.com</U> and follow us on
<U>www.twitter.com/amgen</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of
historical fact, are statements that </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AMGEN ANNOUNCES SUCCESSION PLANS FOR TWO EXECUTIVE OFFICERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> PAGE
 3
 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political,
regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including
those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> and any subsequent periodic reports on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> and <FONT STYLE="white-space:nowrap">Form&nbsp;8-K.</FONT> Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation
to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No forward-looking
statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory
developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition,
sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by
regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive
regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government
investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate
integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may
be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities and
also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to
many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no
guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our
distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material
adverse effect on sales of the affected products and on our business and results of operations. Our efforts to acquire other companies or products and to integrate the operations of companies we have acquired may not be successful. A breakdown,
cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or
limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AMGEN ANNOUNCES SUCCESSION PLANS FOR TWO EXECUTIVE OFFICERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> PAGE
 4
 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONTACT: Amgen, Thousand Oaks </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trish Hawkins, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">805-447-5631</FONT></FONT> (media) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kristen Davis, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">805-447-3008</FONT></FONT> (media) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arvind Sood,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">805-447-1060</FONT></FONT> (investors) </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g583316g86k48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g583316g86k48.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !% ,P# 2(  A$! Q$!_\0
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MF_%K]DFS\%/<QKXC^'S/:36S-B26T>1G@F [K\QC/H4&>HSTO_!57]@;Q/\
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M.6G%35[Q>\6EL[_@?3]%%%?@9_2H4444 %%%% !1110 4444 %%%% !1110
>4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
